Skip to content
A Green Sign – Lifestyle
Author:
Kayak Therapeutics, Inc.
Kayak Therapeutics Announces IND Clearance for KT-300, a Potential First-in-Class TRIM7 Inhibitor for RAS-Driven Cancers
November 5, 2026